Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to a winding down of the seed business and reduced demand for crop inputs in Argentina [6][7][8] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offset by growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7][8] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of 5 to 6 months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10% to 12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, attributing them to a combination of macroeconomic shifts in Argentina and changes in the HB4 seed business strategy [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][22] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous quarter, reflecting repayments of unsecured public bonds and working capital loans [17][18] - Cash and cash equivalents totaled $34.6 million, resulting in a net financial debt of $220.8 million as of June 30, 2025 [18] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management emphasized cash generation and profitability expansion as key metrics, with less priority on top-line growth under current circumstances [24][25] Question: Can you elaborate on cost savings initiatives? - Management indicated that cost savings of $3 to $3.5 million per quarter are expected, achieved through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in fiscal 2025? - Management clarified that the gross profit from Syngenta for the fiscal year was approximately $18 million, with no upfront payment recognized this year [34][36] Question: What is the outlook for the HB4 product? - Management highlighted a significant agreement with GDM to reposition HB4 technology for weed control, which is expected to generate revenues in the upcoming fiscal year [42][43] Question: How is the inventory situation in Argentina? - Management noted that inventory levels have been almost depleted, indicating a potential recovery in sales as planting needs arise [60][61]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to the winding down of the seed business and reduced demand for crop inputs in Argentina [6][8][9] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offsetting growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7] - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of five to six months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10%-12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, primarily due to macroeconomic shifts in Argentina and a lack of inventory incentives for clients [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][21] - Management emphasized the importance of cash generation and profitability expansion over top-line growth in the current environment [25][26] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous year, with cash and equivalents totaling $34.6 million [17][18] - The company is working closely with creditors to comply with financial obligations and manage upcoming debt maturities [20] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management indicated that cash generation and profitability expansion will be key metrics, with less emphasis on top-line growth under current circumstances [25][26] Question: Can you elaborate on cost savings initiatives? - Management expects to achieve quarterly savings of $3 million-$3.5 million through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in FY2025? - The gross profit from the Syngenta agreement for FY2025 was approximately $18 million, down from $16 million in the previous year [35][37] Question: What efforts have been made regarding the HB4 product? - Management highlighted a key agreement in soybeans to reposition HB4 technology, which is expected to generate revenues in the upcoming fiscal year [43][44] Question: What is the current state of inventories in the channel? - Management noted that inventory levels in Argentina have been almost depleted, indicating a potential recovery in sales [62][63]

Core Viewpoint - SynBioCon reports that Jiangsu Siweibo Biotechnology Co., Ltd. has successfully signed a multi-million B round investment agreement with Shenzhen Jiadao Green Low-Carbon Investment Fund, which will inject strong momentum into the company's continuous development. Notably, Ant Financial Chairman Jing Xiandong continues to invest in this round, demonstrating confidence in the company's prospects [2][4]. Company Overview - Siweibo is a leading enterprise in the agricultural microbiology sector and is a key laboratory for green intelligent fertilizers under the Ministry of Agriculture and Rural Affairs. The company has established a comprehensive research, production, sales, and service system that includes core technologies such as microbial strain exploration, high-throughput screening, molecular biology research, active gene regulation, metabolite preparation, and customized applications of composite microorganisms [4]. Funding Utilization - The funds from this round of financing will primarily be used for agricultural biotechnology research and development, industrial investment layout, and team building. By increasing R&D investment, Siweibo aims to accelerate the productization and industrialization of core technologies, enhancing its technological advantages and market competitiveness in areas such as microbial fertilizers and agricultural waste resource utilization [4]. Strategic Goals - Siweibo plans to expand its business footprint through industrial investment layout, strengthen cooperation with upstream and downstream enterprises, and improve overall operational efficiency. Enhanced team building will provide talent support for continuous innovation and stable development [4]. Future Outlook - Siweibo intends to leverage the funds and strategic resources obtained from this financing to accelerate technological innovation and product upgrades, providing high-quality products and services to a broader customer base and creating greater value for society. With the growing demand for agricultural green development, Siweibo is expected to play a leading role in the agricultural biotechnology field, driving innovation and development in the industry [4].